Literature DB >> 9247096

Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.

M Railo1, J Lundin, C Haglund, K von Smitten, K von Boguslawsky, S Nordling.   

Abstract

The prognostic value of Ki-67, p53 and ER immunohistochemical labelling and flow-cytometric S-phase fraction and ploidy was evaluated in 212 pT1N0M0 breast carcinomas. The mean follow-up time was 8.3 years. Patients with breast carcinomas with high Ki-67 expression (> or = 10%) had a less favourable disease-free survival than those with low Ki-67 expression (< 10%) (p = 0.008). A positive p53 staining and high SPF were associated with a less favourable disease-free survival although it did not reach statistical significance. The subset of patients with ER negative, Ki-67 > or = 10% and p53 > or = 20% tumours, had a shorter disease-free survival compared with that of all the other patients (p = 0.03). We conclude that the potential value of Ki-67 labelling for prognostic evaluation of T1N0M0 breast carcinoma is good.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247096     DOI: 10.3109/02841869709001282

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  16 in total

Review 1.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 2.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers.

Authors:  A Ravaioli; L Bagli; A Zucchini; F Monti
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

3.  Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis.

Authors:  Yawara Omoto; Masafumi Kurosumi; Yasuo Hozumi; Hanako Oba; Kaori Kawanowa; Hiroyuki Takei; Yoshikazu Yasuda
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

4.  Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

5.  Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression.

Authors:  Alessandro Sgambato; Mario Migaldi; Micaela Montanari; Andrea Camerini; Andrea Brancaccio; Giulio Rossi; Rodolfo Cangiano; Carmen Losasso; Giovanni Capelli; Gian Paolo Trentini; Achille Cittadini
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

6.  Ki-67 biomarker in breast cancer of Indian women.

Authors:  Amit V Patil; Rajeev Singhai; Rahul S Bhamre; Vinayak W Patil
Journal:  N Am J Med Sci       Date:  2011-03

7.  Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Russell Burcombe; George D Wilson; Mitch Dowsett; Ifty Khan; Paul I Richman; Frances Daley; Simone Detre; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006-06-21       Impact factor: 6.466

8.  Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma.

Authors:  R L Huuhtanen; C P Blomqvist; T A Wiklund; T O Böhling; M J Virolainen; E J Tukiainen; B Tribukait; L C Andersson
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study.

Authors:  Shekhar Sharma; K R Hiran; K Pavithran; D K Vijaykumar
Journal:  World J Surg Oncol       Date:  2009-03-30       Impact factor: 2.754

10.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

Authors:  E de Azambuja; F Cardoso; G de Castro; M Colozza; M S Mano; V Durbecq; C Sotiriou; D Larsimont; M J Piccart-Gebhart; M Paesmans
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.